Global Psoriatic Arthritis Treatment
Global Psoriatic Arthritis Treatment

Psoriatic Arthritis Treatment Comprehensive Study by Treatment (Medications (NSAIDs, Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic Agents and Others), Surgical Procedures (Joint Replacement Surgery), Steroid Injections), Route of Administration (Oral, Parentaral, Topical), End-users (Hospitals, Clinics, Ambulatory Surgical Centres), Distribution Channel (Hospital Pharamacies, Retail Pharamcies, Online, Others), Diagnosis (Imaging Tests {X-rays and Magnetic resonance imaging (MRI)}, Laboratory tests (Rheumatoid factor (RF) and Joint fluid test)) Players and Region - Global Market Outlook to 2026

Psoriatic Arthritis Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 222 Pages 189 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Psoriatic Arthritis Treatment Market?

About 7.5 million Americans have psoriasis and around 30 percent of these people develop psoriatic arthritis. Psoriatic arthritis is a form of inflammatory arthritis that combines the swollen, sore joints of arthritis with psoriasis. Its primary symptoms involve joint pain, stiffness and swelling. It can affect any part of the body such as the fingertips and spine and can range from relatively mild to severe. There is no cure for psoriatic arthritis and the treatment used for controlling symptoms and preventing damage to joints.

The market study is being classified and major geographies with country level break-up.

Novartis International AG (Switzerland), Abbvie (United States), Eli Lilly and Company (United States), Roche Holding AG (Switzerland), Merck & Co. (United States), Amgen (United States), Bristol Myers Squibb (United States), Celgene Corporation (United States), Janssen Pharmaceutica (Belgium) and Bausch Health Companies Inc. (Canada) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Psoriatic Arthritis Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Psoriatic Arthritis Treatment market by Type, Application and Region.

On the basis of geography, the market of Psoriatic Arthritis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Psoriatic Arthritis among People
  • Increased Number of Diagnostic Centres
  • Rise in the Healthcare Infrastructure in Developing Regions

Market Trend
  • Technological Advancements in The Medical Science
  • Increasing Consumer Awareness

Restraints
  • No Complete Cure for Psoriatic Arthritis
  • Side Effects of the Medicines

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Increasing Demand for Cost-Effective Medicines

Challenges
  • Stringent Government Rules and Regulations


In August 2019, Amgen has announced that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire worldwide rights to Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities.


Key Target Audience
Psoriatic Arthritis Treatment Providers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Treatment
  • Medications (NSAIDs, Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic Agents and Others)
  • Surgical Procedures (Joint Replacement Surgery)
  • Steroid Injections

By Route of Administration
  • Oral
  • Parentaral
  • Topical

By End-users
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres

By Distribution Channel
  • Hospital Pharamacies
  • Retail Pharamcies
  • Online
  • Others

By Diagnosis
  • Imaging Tests {X-rays and Magnetic resonance imaging (MRI)}
  • Laboratory tests (Rheumatoid factor (RF) and Joint fluid test)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Psoriatic Arthritis among People
      • 3.2.2. Increased Number of Diagnostic Centres
      • 3.2.3. Rise in the Healthcare Infrastructure in Developing Regions
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in The Medical Science
      • 3.4.2. Increasing Consumer Awareness
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Psoriatic Arthritis Treatment, by Treatment, Route of Administration, End-users, Distribution Channel, Diagnosis and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Psoriatic Arthritis Treatment (Value)
      • 5.2.1. Global Psoriatic Arthritis Treatment by: Treatment (Value)
        • 5.2.1.1. Medications (NSAIDs, Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic Agents and Others)
        • 5.2.1.2. Surgical Procedures (Joint Replacement Surgery)
        • 5.2.1.3. Steroid Injections
      • 5.2.2. Global Psoriatic Arthritis Treatment by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parentaral
        • 5.2.2.3. Topical
      • 5.2.3. Global Psoriatic Arthritis Treatment by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Ambulatory Surgical Centres
      • 5.2.4. Global Psoriatic Arthritis Treatment by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharamacies
        • 5.2.4.2. Retail Pharamcies
        • 5.2.4.3. Online
        • 5.2.4.4. Others
      • 5.2.5. Global Psoriatic Arthritis Treatment by: Diagnosis (Value)
        • 5.2.5.1. Imaging Tests {X-rays and Magnetic resonance imaging (MRI)}
        • 5.2.5.2. Laboratory tests (Rheumatoid factor (RF) and Joint fluid test)
      • 5.2.6. Global Psoriatic Arthritis Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Psoriatic Arthritis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbvie (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche Holding AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol Myers Squibb (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Celgene Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Janssen Pharmaceutica (Belgium)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bausch Health Companies Inc. (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Psoriatic Arthritis Treatment Sale, by Treatment, Route of Administration, End-users, Distribution Channel, Diagnosis and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Psoriatic Arthritis Treatment (Value)
      • 7.2.1. Global Psoriatic Arthritis Treatment by: Treatment (Value)
        • 7.2.1.1. Medications (NSAIDs, Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic Agents and Others)
        • 7.2.1.2. Surgical Procedures (Joint Replacement Surgery)
        • 7.2.1.3. Steroid Injections
      • 7.2.2. Global Psoriatic Arthritis Treatment by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parentaral
        • 7.2.2.3. Topical
      • 7.2.3. Global Psoriatic Arthritis Treatment by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Ambulatory Surgical Centres
      • 7.2.4. Global Psoriatic Arthritis Treatment by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharamacies
        • 7.2.4.2. Retail Pharamcies
        • 7.2.4.3. Online
        • 7.2.4.4. Others
      • 7.2.5. Global Psoriatic Arthritis Treatment by: Diagnosis (Value)
        • 7.2.5.1. Imaging Tests {X-rays and Magnetic resonance imaging (MRI)}
        • 7.2.5.2. Laboratory tests (Rheumatoid factor (RF) and Joint fluid test)
      • 7.2.6. Global Psoriatic Arthritis Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Psoriatic Arthritis Treatment: by Treatment(USD Million)
  • Table 2. Psoriatic Arthritis Treatment Medications (NSAIDs, Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic Agents and Others) , by Region USD Million (2015-2020)
  • Table 3. Psoriatic Arthritis Treatment Surgical Procedures (Joint Replacement Surgery) , by Region USD Million (2015-2020)
  • Table 4. Psoriatic Arthritis Treatment Steroid Injections , by Region USD Million (2015-2020)
  • Table 5. Psoriatic Arthritis Treatment: by Route of Administration(USD Million)
  • Table 6. Psoriatic Arthritis Treatment Oral , by Region USD Million (2015-2020)
  • Table 7. Psoriatic Arthritis Treatment Parentaral , by Region USD Million (2015-2020)
  • Table 8. Psoriatic Arthritis Treatment Topical , by Region USD Million (2015-2020)
  • Table 9. Psoriatic Arthritis Treatment: by End-users(USD Million)
  • Table 10. Psoriatic Arthritis Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 11. Psoriatic Arthritis Treatment Clinics , by Region USD Million (2015-2020)
  • Table 12. Psoriatic Arthritis Treatment Ambulatory Surgical Centres , by Region USD Million (2015-2020)
  • Table 13. Psoriatic Arthritis Treatment: by Distribution Channel(USD Million)
  • Table 14. Psoriatic Arthritis Treatment Hospital Pharamacies , by Region USD Million (2015-2020)
  • Table 15. Psoriatic Arthritis Treatment Retail Pharamcies , by Region USD Million (2015-2020)
  • Table 16. Psoriatic Arthritis Treatment Online , by Region USD Million (2015-2020)
  • Table 17. Psoriatic Arthritis Treatment Others , by Region USD Million (2015-2020)
  • Table 18. Psoriatic Arthritis Treatment: by Diagnosis(USD Million)
  • Table 19. Psoriatic Arthritis Treatment Imaging Tests {X-rays and Magnetic resonance imaging (MRI)} , by Region USD Million (2015-2020)
  • Table 20. Psoriatic Arthritis Treatment Laboratory tests (Rheumatoid factor (RF) and Joint fluid test) , by Region USD Million (2015-2020)
  • Table 21. South America Psoriatic Arthritis Treatment, by Country USD Million (2015-2020)
  • Table 22. South America Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 23. South America Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 24. South America Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 25. South America Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 26. South America Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 27. Brazil Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 28. Brazil Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 29. Brazil Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 30. Brazil Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 31. Brazil Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 32. Argentina Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 33. Argentina Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 34. Argentina Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 35. Argentina Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 36. Argentina Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 37. Rest of South America Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 38. Rest of South America Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 39. Rest of South America Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 40. Rest of South America Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 41. Rest of South America Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 42. Asia Pacific Psoriatic Arthritis Treatment, by Country USD Million (2015-2020)
  • Table 43. Asia Pacific Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 44. Asia Pacific Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 45. Asia Pacific Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 46. Asia Pacific Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 47. Asia Pacific Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 48. China Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 49. China Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 50. China Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 51. China Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 52. China Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 53. Japan Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 54. Japan Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 55. Japan Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 56. Japan Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 57. Japan Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 58. India Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 59. India Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 60. India Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 61. India Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 62. India Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 63. South Korea Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 64. South Korea Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 65. South Korea Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 66. South Korea Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 67. South Korea Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 68. Taiwan Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 69. Taiwan Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 70. Taiwan Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 71. Taiwan Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 72. Taiwan Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 73. Australia Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 74. Australia Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 75. Australia Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 76. Australia Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 77. Australia Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 83. Europe Psoriatic Arthritis Treatment, by Country USD Million (2015-2020)
  • Table 84. Europe Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 85. Europe Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 86. Europe Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 87. Europe Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 88. Europe Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 89. Germany Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 90. Germany Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 91. Germany Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 92. Germany Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 93. Germany Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 94. France Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 95. France Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 96. France Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 97. France Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 98. France Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 99. Italy Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 100. Italy Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 101. Italy Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 102. Italy Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 103. Italy Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 104. United Kingdom Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 105. United Kingdom Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 106. United Kingdom Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 107. United Kingdom Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 108. United Kingdom Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 109. Netherlands Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 110. Netherlands Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 111. Netherlands Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 112. Netherlands Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 113. Netherlands Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 114. Rest of Europe Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 115. Rest of Europe Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 116. Rest of Europe Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 117. Rest of Europe Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 118. Rest of Europe Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 119. MEA Psoriatic Arthritis Treatment, by Country USD Million (2015-2020)
  • Table 120. MEA Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 121. MEA Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 122. MEA Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 123. MEA Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 124. MEA Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 125. Middle East Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 126. Middle East Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 127. Middle East Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 128. Middle East Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 129. Middle East Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 130. Africa Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 131. Africa Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 132. Africa Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 133. Africa Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 134. Africa Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 135. North America Psoriatic Arthritis Treatment, by Country USD Million (2015-2020)
  • Table 136. North America Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 137. North America Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 138. North America Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 139. North America Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 140. North America Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 141. United States Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 142. United States Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 143. United States Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 144. United States Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 145. United States Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 146. Canada Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 147. Canada Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 148. Canada Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 149. Canada Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 150. Canada Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 151. Mexico Psoriatic Arthritis Treatment, by Treatment USD Million (2015-2020)
  • Table 152. Mexico Psoriatic Arthritis Treatment, by Route of Administration USD Million (2015-2020)
  • Table 153. Mexico Psoriatic Arthritis Treatment, by End-users USD Million (2015-2020)
  • Table 154. Mexico Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 155. Mexico Psoriatic Arthritis Treatment, by Diagnosis USD Million (2015-2020)
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Psoriatic Arthritis Treatment: by Treatment(USD Million)
  • Table 167. Psoriatic Arthritis Treatment Medications (NSAIDs, Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic Agents and Others) , by Region USD Million (2021-2026)
  • Table 168. Psoriatic Arthritis Treatment Surgical Procedures (Joint Replacement Surgery) , by Region USD Million (2021-2026)
  • Table 169. Psoriatic Arthritis Treatment Steroid Injections , by Region USD Million (2021-2026)
  • Table 170. Psoriatic Arthritis Treatment: by Route of Administration(USD Million)
  • Table 171. Psoriatic Arthritis Treatment Oral , by Region USD Million (2021-2026)
  • Table 172. Psoriatic Arthritis Treatment Parentaral , by Region USD Million (2021-2026)
  • Table 173. Psoriatic Arthritis Treatment Topical , by Region USD Million (2021-2026)
  • Table 174. Psoriatic Arthritis Treatment: by End-users(USD Million)
  • Table 175. Psoriatic Arthritis Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 176. Psoriatic Arthritis Treatment Clinics , by Region USD Million (2021-2026)
  • Table 177. Psoriatic Arthritis Treatment Ambulatory Surgical Centres , by Region USD Million (2021-2026)
  • Table 178. Psoriatic Arthritis Treatment: by Distribution Channel(USD Million)
  • Table 179. Psoriatic Arthritis Treatment Hospital Pharamacies , by Region USD Million (2021-2026)
  • Table 180. Psoriatic Arthritis Treatment Retail Pharamcies , by Region USD Million (2021-2026)
  • Table 181. Psoriatic Arthritis Treatment Online , by Region USD Million (2021-2026)
  • Table 182. Psoriatic Arthritis Treatment Others , by Region USD Million (2021-2026)
  • Table 183. Psoriatic Arthritis Treatment: by Diagnosis(USD Million)
  • Table 184. Psoriatic Arthritis Treatment Imaging Tests {X-rays and Magnetic resonance imaging (MRI)} , by Region USD Million (2021-2026)
  • Table 185. Psoriatic Arthritis Treatment Laboratory tests (Rheumatoid factor (RF) and Joint fluid test) , by Region USD Million (2021-2026)
  • Table 186. South America Psoriatic Arthritis Treatment, by Country USD Million (2021-2026)
  • Table 187. South America Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 188. South America Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 189. South America Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 190. South America Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 191. South America Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 192. Brazil Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 193. Brazil Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 194. Brazil Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 195. Brazil Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 196. Brazil Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 197. Argentina Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 198. Argentina Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 199. Argentina Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 200. Argentina Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 201. Argentina Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 202. Rest of South America Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 203. Rest of South America Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 204. Rest of South America Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 205. Rest of South America Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 206. Rest of South America Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 207. Asia Pacific Psoriatic Arthritis Treatment, by Country USD Million (2021-2026)
  • Table 208. Asia Pacific Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 209. Asia Pacific Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 210. Asia Pacific Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 211. Asia Pacific Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 212. Asia Pacific Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 213. China Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 214. China Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 215. China Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 216. China Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 217. China Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 218. Japan Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 219. Japan Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 220. Japan Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 221. Japan Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 222. Japan Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 223. India Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 224. India Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 225. India Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 226. India Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 227. India Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 228. South Korea Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 229. South Korea Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 230. South Korea Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 231. South Korea Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 232. South Korea Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 233. Taiwan Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 234. Taiwan Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 235. Taiwan Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 236. Taiwan Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 237. Taiwan Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 238. Australia Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 239. Australia Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 240. Australia Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 241. Australia Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 242. Australia Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 243. Rest of Asia-Pacific Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 244. Rest of Asia-Pacific Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 245. Rest of Asia-Pacific Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 246. Rest of Asia-Pacific Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 247. Rest of Asia-Pacific Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 248. Europe Psoriatic Arthritis Treatment, by Country USD Million (2021-2026)
  • Table 249. Europe Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 250. Europe Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 251. Europe Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 252. Europe Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 253. Europe Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 254. Germany Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 255. Germany Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 256. Germany Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 257. Germany Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 258. Germany Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 259. France Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 260. France Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 261. France Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 262. France Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 263. France Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 264. Italy Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 265. Italy Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 266. Italy Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 267. Italy Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 268. Italy Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 269. United Kingdom Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 270. United Kingdom Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 271. United Kingdom Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 272. United Kingdom Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 273. United Kingdom Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 274. Netherlands Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 275. Netherlands Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 276. Netherlands Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 277. Netherlands Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 278. Netherlands Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 279. Rest of Europe Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 280. Rest of Europe Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 281. Rest of Europe Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 282. Rest of Europe Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 283. Rest of Europe Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 284. MEA Psoriatic Arthritis Treatment, by Country USD Million (2021-2026)
  • Table 285. MEA Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 286. MEA Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 287. MEA Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 288. MEA Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 289. MEA Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 290. Middle East Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 291. Middle East Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 292. Middle East Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 293. Middle East Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 294. Middle East Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 295. Africa Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 296. Africa Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 297. Africa Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 298. Africa Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 299. Africa Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 300. North America Psoriatic Arthritis Treatment, by Country USD Million (2021-2026)
  • Table 301. North America Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 302. North America Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 303. North America Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 304. North America Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 305. North America Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 306. United States Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 307. United States Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 308. United States Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 309. United States Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 310. United States Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 311. Canada Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 312. Canada Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 313. Canada Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 314. Canada Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 315. Canada Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 316. Mexico Psoriatic Arthritis Treatment, by Treatment USD Million (2021-2026)
  • Table 317. Mexico Psoriatic Arthritis Treatment, by Route of Administration USD Million (2021-2026)
  • Table 318. Mexico Psoriatic Arthritis Treatment, by End-users USD Million (2021-2026)
  • Table 319. Mexico Psoriatic Arthritis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 320. Mexico Psoriatic Arthritis Treatment, by Diagnosis USD Million (2021-2026)
  • Table 321. Research Programs/Design for This Report
  • Table 322. Key Data Information from Secondary Sources
  • Table 323. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Psoriatic Arthritis Treatment: by Treatment USD Million (2015-2020)
  • Figure 5. Global Psoriatic Arthritis Treatment: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Psoriatic Arthritis Treatment: by End-users USD Million (2015-2020)
  • Figure 7. Global Psoriatic Arthritis Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Psoriatic Arthritis Treatment: by Diagnosis USD Million (2015-2020)
  • Figure 9. South America Psoriatic Arthritis Treatment Share (%), by Country
  • Figure 10. Asia Pacific Psoriatic Arthritis Treatment Share (%), by Country
  • Figure 11. Europe Psoriatic Arthritis Treatment Share (%), by Country
  • Figure 12. MEA Psoriatic Arthritis Treatment Share (%), by Country
  • Figure 13. North America Psoriatic Arthritis Treatment Share (%), by Country
  • Figure 14. Global Psoriatic Arthritis Treatment share by Players 2020 (%)
  • Figure 15. Global Psoriatic Arthritis Treatment share by Players (Top 3) 2020(%)
  • Figure 16. Global Psoriatic Arthritis Treatment share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. Abbvie (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbvie (United States) Revenue: by Geography 2020
  • Figure 22. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 24. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 26. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 28. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 29. Amgen (United States) Revenue: by Geography 2020
  • Figure 30. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 31. Bristol Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 32. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 33. Celgene Corporation (United States) Revenue: by Geography 2020
  • Figure 34. Janssen Pharmaceutica (Belgium) Revenue, Net Income and Gross profit
  • Figure 35. Janssen Pharmaceutica (Belgium) Revenue: by Geography 2020
  • Figure 36. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 37. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2020
  • Figure 38. Global Psoriatic Arthritis Treatment: by Treatment USD Million (2021-2026)
  • Figure 39. Global Psoriatic Arthritis Treatment: by Route of Administration USD Million (2021-2026)
  • Figure 40. Global Psoriatic Arthritis Treatment: by End-users USD Million (2021-2026)
  • Figure 41. Global Psoriatic Arthritis Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 42. Global Psoriatic Arthritis Treatment: by Diagnosis USD Million (2021-2026)
  • Figure 43. South America Psoriatic Arthritis Treatment Share (%), by Country
  • Figure 44. Asia Pacific Psoriatic Arthritis Treatment Share (%), by Country
  • Figure 45. Europe Psoriatic Arthritis Treatment Share (%), by Country
  • Figure 46. MEA Psoriatic Arthritis Treatment Share (%), by Country
  • Figure 47. North America Psoriatic Arthritis Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Novartis International AG (Switzerland)
  • Abbvie (United States)
  • Eli Lilly and Company (United States)
  • Roche Holding AG (Switzerland)
  • Merck & Co. (United States)
  • Amgen (United States)
  • Bristol Myers Squibb (United States)
  • Celgene Corporation (United States)
  • Janssen Pharmaceutica (Belgium)
  • Bausch Health Companies Inc. (Canada)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation